News articles about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat negative recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aldeyra Therapeutics earned a daily sentiment score of -0.07 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.9782085802821 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Aldeyra Therapeutics (NASDAQ:ALDX) opened at $6.85 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.35 and a quick ratio of 20.35. The stock has a market cap of $130.96, a PE ratio of -4.86 and a beta of 0.53. Aldeyra Therapeutics has a 12 month low of $3.80 and a 12 month high of $11.90.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.09. analysts anticipate that Aldeyra Therapeutics will post -1.39 earnings per share for the current year.
A number of equities research analysts have recently issued reports on the stock. ValuEngine cut shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Zacks Investment Research cut shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Finally, Cantor Fitzgerald assumed coverage on shares of Aldeyra Therapeutics in a report on Tuesday, October 24th. They set an “overweight” rating and a $22.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Aldeyra Therapeutics has an average rating of “Buy” and a consensus price target of $17.42.
TRADEMARK VIOLATION WARNING: “Somewhat Negative News Coverage Somewhat Unlikely to Affect Aldeyra Therapeutics (ALDX) Share Price” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/14/somewhat-negative-news-coverage-somewhat-unlikely-to-impact-aldeyra-therapeutics-aldx-share-price-updated-updated.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.